Novartis' vaccines business gets chance to prove itself

ZURICH (Reuters) - The European Medicines Agency has thrown Novartis' loss-making vaccines business a lifeline by recommending its meningitis B shot for approval, which means the pressure is on to make the product a commercial success. Novartis paid $5.1 billion to gain full control of U.S. vaccine maker Chiron Corp in 2006 in a major bet on vaccines designed to reduce its dependence on ...